Those with a vested interest in the development of new cancer therapies have been spoilt once again by data presented at the ongoing annual meeting of the American Society of Clinical Oncology (ASCO). For the third year in a row, immuno-oncology treatments – particularly the PD-1/PD-L1 inhibitors – have dominated headlines.
Source Forbes - Business http://ift.tt/1JdFWmi
ليست هناك تعليقات:
إرسال تعليق